What does this research mean for the field?

Chronic beta-adrenoceptor blockade prevents the reduction of myocardial beta-receptor density and attenuates beta-adrenergic subsensitivity in right-sided congestive heart failure, indicating that excessive sympathetic stimulation drives receptor downregulation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine whether chronic beta-receptor blockade prevents the downregulation of myocardial beta-adrenergic receptor density and responsiveness in experimental right heart failure.

July 1, 1991CirculationOpen Access

Chronic beta-adrenoceptor blockade prevents the development of beta-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs.

View Full Paper

Ask AI

Bookmark

Why the study?

Does nadolol prevent the development of beta-adrenergic subsensitivity in dogs with experimental right-sided congestive heart failure?

Key Points

To determine whether chronic beta-receptor blockade prevents the downregulation of myocardial beta-adrenergic receptor density and responsiveness in experimental right heart failure.
Administered oral nadolol (40 mg/day) or no drug for 5 weeks to dogs with early-stage experimental right heart failure and sham-operated controls.
Measured hemodynamics, plasma and myocardial norepinephrine levels, myocardial beta-receptor density, and adenylate cyclase activity 5 days after nadolol discontinuation.
Nadolol treatment prevented the downregulation of myocardial beta-receptor density and attenuated the loss of cardiac beta-adrenergic sensitivity in dogs with right heart failure.
Treatment did not alter right ventricular hypertrophy, elevated plasma norepinephrine, reductions in myocardial norepinephrine content, or resting hemodynamic parameters.

Structured PICO

Does nadolol prevent the development of beta-adrenergic subsensitivity in dogs with experimental right-sided congestive heart failure?

Population

Dogs during an early stage of experimental right heart failure and sham-operated dogs

Intervention

Nadolol 40 mg/day orally for 5 weeks

Comparator

No nadolol treatment

Outcome

Myocardial beta-receptor density and cardiac beta-adrenergic sensitivitysurrogate

Chronic beta-blockade with nadolol prevents beta-receptor downregulation and subsensitivity in experimental right heart failure, suggesting a role for excessive sympathetic stimulation in these changes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports sympathetic overdrive in beta-receptor downregulation in right HF; hypothesis-generating for beta-blockade but leaves clinical translation open.

Cite This Study

Liang et al. (1991) studied this question.

synapsesocial.com/papers/6a19bb6b443d3ecd7cdef1d9 https://doi.org/10.1161/01.cir.84.1.254

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Implication

Supports sympathetic overdrive in beta-receptor downregulation in right HF; hypothesis-generating for beta-blockade but leaves clinical translation open.

Chronic beta-adrenoceptor blockade prevents the development of beta-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs.

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Chronic beta-adrenoceptor blockade prevents the development of beta-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs.

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider